Terms: = Pancreatic cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Prognosis
190 results:
1. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.
Qiu X; Lu C; Sha H; Zhu Y; Kong W; Tong F; Wang Q; Meng F; Liu B; Du J
Front Immunol; 2024; 15():1210859. PubMed ID: 38361920
[TBL] [Abstract] [Full Text] [Related]
3. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.
Xu C; Zhu M; Wang Q; Cui J; Huang Y; Huang X; Huang J; Gai J; Li G; Qiao P; Zeng X; Ju D; Wan Y; Zhang X
J Nanobiotechnology; 2023 Nov; 21(1):410. PubMed ID: 37932752
[TBL] [Abstract] [Full Text] [Related]
4.
Tobi M; Weinstein D; Kim M; Hatfield J; Sochacki P; Levi E; An T; Hamre M; Tolia V; Fligiel S; Marepally R; Hallman J; Bapat B; Yuan M; McVicker B; Gallinger S
Curr Oncol; 2023 Aug; 30(9):7950-7963. PubMed ID: 37754493
[TBL] [Abstract] [Full Text] [Related]
5. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type pancreatic cancer.
Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
[TBL] [Abstract] [Full Text] [Related]
6. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.
Sutera PA; Shetty AC; Hakansson A; Van der Eecken K; Song Y; Liu Y; Chang J; Fonteyne V; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Rana Z; Hodges T; Hamid A; Roberts N; Song DY; Pienta K; Ross AE; Feng F; Joniau S; Spratt D; Gillessen S; Attard G; James ND; Lotan T; Davicioni E; Sweeney C; Tran PT; Deek MP; Ost P
Ann Oncol; 2023 Jul; 34(7):605-614. PubMed ID: 37164128
[TBL] [Abstract] [Full Text] [Related]
7. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
[TBL] [Abstract] [Full Text] [Related]
8. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK; Ueno M; Yoo C; Finn RS; Furuse J; Ren Z; Yau T; Klümpen HJ; Chan SL; Ozaka M; Verslype C; Bouattour M; Park JO; Barajas O; Pelzer U; Valle JW; Yu L; Malhotra U; Siegel AB; Edeline J; Vogel A;
Lancet; 2023 Jun; 401(10391):1853-1865. PubMed ID: 37075781
[TBL] [Abstract] [Full Text] [Related]
9. Discordance Between Conventional and Detailed Lymph Node Analysis in Resected, Node-negative pancreatic or Ampullary Adenocarcinomas and Association With Adverse Survival Outcomes: A Single-institution Analysis.
Elshami M; Ammoun AK; Mneimneh WS; Stitzel HJ; Hue JJ; Wu VS; Kyasaram RK; Shanahan J; Musonza T; Ammori JB; Hardacre JM; Winter JM; ElHag M; Ocuin LM
Ann Surg; 2023 Dec; 278(6):e1204-e1209. PubMed ID: 37051926
[TBL] [Abstract] [Full Text] [Related]
10. Somatostatin-analog effect on pancreatic fistula after radical gastrectomy: a pilot randomized controlled trial.
Sha S; Qiao W; Feng R; Lian G; Chen Y; Peng L; Wang J; Li L; Tian F; Jing C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6329-6339. PubMed ID: 36745222
[TBL] [Abstract] [Full Text] [Related]
11. Risk of Psychiatric Disorders Among Spouses of Patients With cancer in Denmark and Sweden.
Hu K; Liu Q; László KD; Wei D; Yang F; Fall K; Adami HO; Ye W; Valdimarsdóttir UA; Li J; Fang F
JAMA Netw Open; 2023 Jan; 6(1):e2249560. PubMed ID: 36602801
[TBL] [Abstract] [Full Text] [Related]
12. Diabetes mellitus impacts on expression of DNA mismatch repair protein pms2 and tumor microenvironment in pancreatic ductal adenocarcinoma.
Pan X; Mizukami H; Hara Y; Yamada T; Yamazaki K; Kudoh K; Takeuchi Y; Sasaki T; Kushibiki H; Igawa A; Hakamada K
J Diabetes Investig; 2023 Jan; 14(1):132-144. PubMed ID: 36453157
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels.
Ono Y; Inoue Y; Ito H; Sasaki T; Takeda T; Ozaka M; Sasahira N; Hiratsuka M; Matsueda K; Oba A; Sato T; Saiura A; Takahashi Y
HPB (Oxford); 2023 Jan; 25(1):100-108. PubMed ID: 36280425
[TBL] [Abstract] [Full Text] [Related]
14. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for advanced pancreatic and periampullary adenocarcinoma.
Thosani N; Cen P; Rowe J; Guha S; Bailey-Lundberg JM; Bhakta D; Patil P; Wray CJ
Sci Rep; 2022 Oct; 12(1):16516. PubMed ID: 36192558
[TBL] [Abstract] [Full Text] [Related]
15. Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis.
Debernardi S; Blyuss O; Rycyk D; Srivastava K; Jeon CY; Cai H; Cai Q; Shu XO; Crnogorac-Jurcevic T
Int J Cancer; 2023 Feb; 152(4):769-780. PubMed ID: 36093581
[TBL] [Abstract] [Full Text] [Related]
16. Evaluating the Significance of Pancreatobiliary Fluorescence In Situ Hybridization Polysomy on prognosis in De Novo Cholangiocarcinoma.
Ji H; Barr Fritcher EG; Yin J; Bainter TM; Zemla TJ; Gores GJ; Halling KC; Kipp BR; Roberts LR
Clin Transl Gastroenterol; 2022 Oct; 13(10):e00523. PubMed ID: 36000989
[TBL] [Abstract] [Full Text] [Related]
17. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases.
Zhang G; Li B; Yin X; Gao S; Shen S; Wang H; Shi X; Liu W; Zheng K; Jing W; Zhang Y; He T; Li G; Hu X; Guo S; Jin G
Int J Surg; 2022 Aug; 104():106786. PubMed ID: 35868619
[TBL] [Abstract] [Full Text] [Related]
18. Acetyl-Coenzyme A Synthetase 2 Potentiates Macropinocytosis and Muscle Wasting Through Metabolic Reprogramming in pancreatic cancer.
Zhou Z; Ren Y; Yang J; Liu M; Shi X; Luo W; Fung KM; Xu C; Bronze MS; Zhang Y; Houchen CW; Li M
Gastroenterology; 2022 Nov; 163(5):1281-1293.e1. PubMed ID: 35777482
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of 55 patients with multiple endocrine neoplasia type 1-associated insulinoma from a single center in China.
Zhao Y; Yu J; Liu Y; Lyu L; Ping F; Xu L; Li W; Wang O; Xu Q; Wu W; Zhang H; Li Y
Orphanet J Rare Dis; 2022 Jun; 17(1):219. PubMed ID: 35698198
[TBL] [Abstract] [Full Text] [Related]
20. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and prognosis.
Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
[TBL] [Abstract] [Full Text] [Related]
[Next]
